Scientific work

Doç. Dr. Zeynep Yegin Katran

60 publications. The source of the information is stated next to each publication.

Back to profile
  1. Use of omalizumab in chemotherapy rapid drug desensitization: Can anaphylaxis be prevented?

    Allergy, 2023

    Source: ORCID

  2. Successful Treatment of Tuberculosis Combined With Rifampicin Induced Interstitial Nephritis: A Case Report

    International Journal of Nephrology and Kidney Failure, 2023

    DOI 10.16966/2380-5498.235 Open-access full textSource: OpenAlex

  3. Dahili Hastalarda Özel Beslenme ve Diyet Yönetimi

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.2182 Source: OpenAlex

  4. Management of type 1 hypersensitivity reactions to antituberculosis drug: Succesful Desensitization

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1752643/v1 Open-access full textSource: ORCID

  5. Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization

    Allergy Asthma and Clinical Immunology, 2022

    DOI 10.1186/s13223-022-00737-4 PMID 36414980 5 citations (Europe PMC) Open-access full textSource: ORCID

  6. Successful Oxaliplatin Desensitization After Omalizumab Administration

    Research Square, 2022

    DOI 10.21203/rs.3.rs-2313500/v1 Open-access full textSource: ORCID

  7. Treatment and Management of Hypersensitivity Reactions Developed Against Anti-Tuberculosis Drug

    International Journal of Mycobacteriology, 2022

    DOI 10.4103/ijmy.ijmy_78_22 PMID 36260451 7 citations (Europe PMC) Open-access full textSource: ORCID

  8. Tuberculosis Treatment-related Lichenoid Drug Eruptions

    International Journal of Mycobacteriology, 2022

    DOI 10.4103/ijmy.ijmy_151_22 PMID 36510939 Open-access full textSource: ORCID

  9. The predictive value of qSOFA and CURB-65 scores in predicting the hospitalization need and mortality in patients with acute exacerbation of chronic obstructive pulmonary disease

    Italian Journal of Emergency Medicine, 2021

    DOI 10.23736/s2532-1285.20.00039-7 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

    The Clinical Respiratory Journal, 2018

    DOI 10.1111/crj.12726 PMID 29028148 17 citations (Europe PMC) Source: ORCID